Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 13.15 USD -19.33% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Intrinsic Value

The intrinsic value of one AVDL stock under the Base Case scenario is 19.65 USD. Compared to the current market price of 13.15 USD, Avadel Pharmaceuticals PLC is Undervalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AVDL Intrinsic Value
19.65 USD
Undervaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Avadel Pharmaceuticals PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AVDL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AVDL?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Avadel Pharmaceuticals PLC

Provide an overview of the primary business activities
of Avadel Pharmaceuticals PLC.

What unique competitive advantages
does Avadel Pharmaceuticals PLC hold over its rivals?

What risks and challenges
does Avadel Pharmaceuticals PLC face in the near future?

Has there been any significant insider trading activity
in Avadel Pharmaceuticals PLC recently?

Summarize the latest earnings call
of Avadel Pharmaceuticals PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Avadel Pharmaceuticals PLC.

Provide P/S
for Avadel Pharmaceuticals PLC.

Provide P/E
for Avadel Pharmaceuticals PLC.

Provide P/OCF
for Avadel Pharmaceuticals PLC.

Provide P/FCFE
for Avadel Pharmaceuticals PLC.

Provide P/B
for Avadel Pharmaceuticals PLC.

Provide EV/S
for Avadel Pharmaceuticals PLC.

Provide EV/GP
for Avadel Pharmaceuticals PLC.

Provide EV/EBITDA
for Avadel Pharmaceuticals PLC.

Provide EV/EBIT
for Avadel Pharmaceuticals PLC.

Provide EV/OCF
for Avadel Pharmaceuticals PLC.

Provide EV/FCFF
for Avadel Pharmaceuticals PLC.

Provide EV/IC
for Avadel Pharmaceuticals PLC.

Show me price targets
for Avadel Pharmaceuticals PLC made by professional analysts.

What are the Revenue projections
for Avadel Pharmaceuticals PLC?

How accurate were the past Revenue estimates
for Avadel Pharmaceuticals PLC?

What are the Net Income projections
for Avadel Pharmaceuticals PLC?

How accurate were the past Net Income estimates
for Avadel Pharmaceuticals PLC?

What are the EPS projections
for Avadel Pharmaceuticals PLC?

How accurate were the past EPS estimates
for Avadel Pharmaceuticals PLC?

What are the EBIT projections
for Avadel Pharmaceuticals PLC?

How accurate were the past EBIT estimates
for Avadel Pharmaceuticals PLC?

Compare the revenue forecasts
for Avadel Pharmaceuticals PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Avadel Pharmaceuticals PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Avadel Pharmaceuticals PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Avadel Pharmaceuticals PLC compared to its peers.

Compare the P/E ratios
of Avadel Pharmaceuticals PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Avadel Pharmaceuticals PLC with its peers.

Analyze the financial leverage
of Avadel Pharmaceuticals PLC compared to its main competitors.

Show all profitability ratios
for Avadel Pharmaceuticals PLC.

Provide ROE
for Avadel Pharmaceuticals PLC.

Provide ROA
for Avadel Pharmaceuticals PLC.

Provide ROIC
for Avadel Pharmaceuticals PLC.

Provide ROCE
for Avadel Pharmaceuticals PLC.

Provide Gross Margin
for Avadel Pharmaceuticals PLC.

Provide Operating Margin
for Avadel Pharmaceuticals PLC.

Provide Net Margin
for Avadel Pharmaceuticals PLC.

Provide FCF Margin
for Avadel Pharmaceuticals PLC.

Show all solvency ratios
for Avadel Pharmaceuticals PLC.

Provide D/E Ratio
for Avadel Pharmaceuticals PLC.

Provide D/A Ratio
for Avadel Pharmaceuticals PLC.

Provide Interest Coverage Ratio
for Avadel Pharmaceuticals PLC.

Provide Altman Z-Score Ratio
for Avadel Pharmaceuticals PLC.

Provide Quick Ratio
for Avadel Pharmaceuticals PLC.

Provide Current Ratio
for Avadel Pharmaceuticals PLC.

Provide Cash Ratio
for Avadel Pharmaceuticals PLC.

What is the historical Revenue growth
over the last 5 years for Avadel Pharmaceuticals PLC?

What is the historical Net Income growth
over the last 5 years for Avadel Pharmaceuticals PLC?

What is the current Free Cash Flow
of Avadel Pharmaceuticals PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Avadel Pharmaceuticals PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Avadel Pharmaceuticals PLC

Current Assets 125.8m
Cash & Short-Term Investments 71.4m
Receivables 34.3m
Other Current Assets 20.1m
Non-Current Assets 31.7m
PP&E 2.6m
Intangibles 16.8m
Other Non-Current Assets 12.3m
Current Liabilities 44.6m
Accounts Payable 9.8m
Accrued Liabilities 34.6m
Other Current Liabilities 242k
Non-Current Liabilities 42.6m
Other Non-Current Liabilities 42.6m
Efficiency

Earnings Waterfall
Avadel Pharmaceuticals PLC

Revenue
95.1m USD
Cost of Revenue
-5.1m USD
Gross Profit
90m USD
Operating Expenses
-188.8m USD
Operating Income
-98.8m USD
Other Expenses
-7.4m USD
Net Income
-106.2m USD

Free Cash Flow Analysis
Avadel Pharmaceuticals PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Avadel Pharmaceuticals reported a 50% increase in revenue for Q2 2024, driven by strong demand for their narcolepsy drug LUMRYZ. Their net revenue soared to $41.5 million, with a gross profit of $38.7 million. Despite high operating expenses, Avadel is confident in maintaining operating income from Q3 onwards, leading up to an annual revenue of around $168 million. With over 1,900 patients on LUMRYZ and significant payer coverage, the company shows optimism in expanding its market share and meeting FDA's approval for pediatric narcolepsy treatment by September.

What is Earnings Call?
Fundamental Scores

AVDL Profitability Score
Profitability Due Diligence

Avadel Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 1-Year Revenue Growth
Declining ROE
24/100
Profitability
Score

Avadel Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

AVDL Solvency Score
Solvency Due Diligence

Avadel Pharmaceuticals PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
45/100
Solvency
Score

Avadel Pharmaceuticals PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AVDL Price Targets Summary
Avadel Pharmaceuticals PLC

Wall Street analysts forecast AVDL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AVDL is 25.09 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

Lowest
Price Target
20.2 USD
54% Upside
Average
Price Target
25.09 USD
91% Upside
Highest
Price Target
31.5 USD
140% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AVDL?

Click here to dive deeper.

Dividends

Avadel Pharmaceuticals PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AVDL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AVDL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC

Country

Ireland

Industry

Pharmaceuticals

Market Cap

1.3B USD

Dividend Yield

0%

Description

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Contact

DUBLIN
DUBLIN
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
+6364491830.0
www.avadel.com

IPO

1952-01-16

Employees

66

Officers

CEO & Director
Mr. Gregory J. Divis Jr.
Senior VP, Principal Financial and Accounting Officer & CFO
Mr. Thomas S. McHugh
Chief Commercial Officer
Mr. Richard J. Kim
General Counsel & Company Secretary
Mr. Jerad G. Seurer
VP of Corporate and Business Development
Mr. Gregory J. Davis
Vice President of Sales
Mr. Mark W. Elrod
Show More
Vice President of People & Culture
Ms. Angie Woods
Consultant
Dr. Jordan S. Dubow M.D.
Senior Vice President of Technical Operations
Dr. Jason M. Vaughn
Senior Vice President of Medical & Clinical Affairs
Ms. Jennifer Gudeman PharmD
Show Less

See Also

Discover More
What is the Intrinsic Value of one AVDL stock?

The intrinsic value of one AVDL stock under the Base Case scenario is 19.65 USD.

Is AVDL stock undervalued or overvalued?

Compared to the current market price of 13.15 USD, Avadel Pharmaceuticals PLC is Undervalued by 33%.

Back to Top